Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Pfizer may spin off or sell its consumer healthcare division, according to The New York Times.
Here are four drug and medical device companies that made headlines in the past week.
Flexion Therapeutics on Friday earned Food and Drug Administration approval for Zilretta, an extended-release treatment for osteoarthritis knee pain.
Medtronic expects supply chain disruptions caused by Hurricane Maria to cost the company up to $250 million in the second quarter of fiscal year 2018, which ends Oct. 27.
The FDA approved an implantable device, Respicardia's Remede System, which helps fight moderate to severe cases of central sleep apnea, a condition where the brain doesn't send proper signals to the muscles that control breathing during sleep.
California Gov. Jerry Brown is expected to sign a bill into law Monday that will make drug prices more transparent in the state, according to the Mercury News.
Amazon will decide whether to enter the U.S.'s multibillion-dollar prescription drug market before Thanksgiving, according to a company email obtained by CNBC.
The Federal Trade Commission will hold a workshop to address high drug prices Nov. 8.
Baxter International on Thursday recalled one shipment of Intralipid due to temperature control issues.
Here are the four latest drugs or medical devices approved by the Food and Drug Administration in the past week.